Hims & Hers Earnings Call Balances Pain With Growth

Hims & Hers Health, Inc. ((HIMS)) has held its Q1 earnings call. Read on for the main highlights of the call.

Hims & Hers Health’s latest earnings call struck a cautiously optimistic tone as management balanced short-term turbulence against powerful growth drivers. One-time restructuring charges, gross-margin pressure and a GAAP loss weighed on reported results, but strong cash generation, rapid GLP-1 adoption and a raised multi‑year outlook underscored the company’s confidence in its long-term trajectory.

Revenue Growth and Upgraded Outlook

Q1 revenue rose 4% year over year to $608 million, a modest top-line increase as the business digested its recent strategic pivot. Management still raised 2026 revenue guidance to a robust $2.8 billion–$3.0 billion, and set Q2 expectations at $680 million–$700 million, implying an acceleration to 25%–28% growth.

Subscriber and Engagement Momentum

Subscribers climbed 9% from a year ago to nearly 2.6 million, signaling that the platform continues to gain traction despite near-term noise. Weight-loss products are emerging as a powerful engagement engine, with the company on track to add over 100,000 new subscribers monthly and those patients interacting with providers multiple times in their first month.

Branded GLP-1 Surge via Novo Nordisk Partnership

The standout growth story is the rapid uptake of branded GLP-1s, particularly Wegovy, following the new access arrangement with Novo Nordisk. Within six weeks, Hims & Hers fulfilled more than 125,000 Wegovy shipments, and management highlighted strong patient feedback on affordability, efficacy and safety of the pill format.

Adjusted EBITDA and Second-Half Acceleration

Q1 adjusted EBITDA reached $44 million, a 7% margin that reflects ongoing investment in new categories and infrastructure. The company reaffirmed full-year adjusted EBITDA guidance of $275 million–$350 million, and emphasized that profitability should step up sharply in the back half as growing cohorts compound and operating leverage improves.

Cash Flow Strength and Capital Flexibility

Despite headline losses, Hims & Hers delivered $89 million of operating cash flow and $53 million of free cash flow in Q1, underscoring the underlying economics of its subscription model. The balance sheet remains a strategic asset with $751 million in cash and short-term investments and significant capacity left on the share repurchase authorization.

Rapid International Expansion

International revenue hit $78 million in the quarter, nearly ten times the prior year, as acquisitions such as ZAVA and Livewell contributed to scale abroad. Management expects the planned Eucalyptus deal to further extend the company’s footprint across key markets including Australia, the U.K., Germany, Japan and Canada once closed.

Technology, AI and Data as Growth Engines

Hims & Hers is investing aggressively in technology, building an AI team of about 40 people and deploying AI copilots to support providers alongside a Labs AI agent. A broader platform rearchitecture, including no-code tools and configurable workflows, aims to speed new category launches, personalize care and improve efficiency across the ecosystem.

Clinical and Product Validation

The call also highlighted clinical proof points, particularly in testosterone care where 95% of customers relying on the platform saw levels increase within two months. The acquisition of YourBio is intended to deepen this data advantage by enabling at-home blood collection and richer biomarker tracking across treatment journeys.

Strategic Pivot and One-Time Restructuring Costs

The March decision to prioritize branded weight-loss offerings triggered roughly $33 million in restructuring charges that weighed on Q1 results. About $28 million of that was tied to unwinding the compounded GLP-1 supply chain, with the rest related to operations and support, creating noise that management framed as largely nonrecurring.

Gross Margin Compression and Near-Term Headwinds

Reported GAAP gross margin fell to 65% in Q1, though adjusted figures excluding one-time charges stood at about 70%. Management cautioned that margins will remain under pressure as lower-margin specialties like weight loss, labs and international take a bigger mix and shorter one-month shipping cycles change revenue recognition.

GAAP Net Loss and Volatile Metrics

These pivot-related effects contributed to a GAAP net loss of $92 million for the quarter, also reflecting transaction and legal costs. Executives warned that investors should expect some volatility in near-term GAAP ratios as the company anniversaries last year’s weight-loss surge and adjusts to new revenue and shipping patterns.

Constrained Q2 Profitability

Near-term profitability will dip as the company absorbs the cost of its transformation and growth initiatives, with Q2 adjusted EBITDA guided to $35 million–$55 million, or roughly a 7% margin at the midpoint. Management argued that these investments, particularly in weight loss and infrastructure, are essential to unlocking scale and higher margins over time.

Forward-Looking Guidance and Outlook

Looking ahead, Hims & Hers expects rapid revenue expansion to continue, underpinned by strong demand for weight-loss therapies and broader telehealth offerings. The company projects 2026 revenue of $2.8 billion–$3.0 billion and adjusted EBITDA of $275 million–$350 million, betting that rising cohorts, improving marketing efficiency and a verticalized, AI-enabled platform will more than offset today’s margin pressures.

The earnings call painted a picture of a business in transition, trading near-term profitability and clean GAAP optics for scale in high-demand categories like GLP-1 weight loss and international markets. For investors, the key debate is whether the strong cash generation, subscriber momentum and upgraded long-term guidance ultimately justify the current bout of margin compression and accounting turbulence.